Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | FTO | Q9C0B1 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 0.81 |
| ▸ | THRB | P10828 | 2/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12849250 | 1.00 | KDM4E (1.00) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| SCHEMBL2453645 | 1.00 | KDM4E (1.00) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| SCHEMBL150459 | 1.00 | KDM4E (1.00) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| SCHEMBL30142606 | 1.00 | KDM4E (1.00) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| SCHEMBL12083012 | 1.00 | KDM4E (1.00) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| SCHEMBL150460 | 1.00 | KDM4E (1.00) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| Carbamic Acid SCHEMBL2453716 | 0.92 | KDM4E (0.85) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| SCHEMBL31663895 | 0.92 | KDM4E (0.85) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| Ether SCHEMBL7982613 | 0.91 | KDM4E (0.83) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| SCHEMBL4104614 | 0.90 | KDM4E (0.81) | KDM4EMEN1KMT2ACYP2D6TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230324359-A1 | THERAPEUTIC DRUG FOR LIPID-PEROXIDATION-INDUCED DISEASES AND SCREENING METHOD FOR THERAPEUTIC DRUGS FOR LIPID-PEROXIDATION-INDUCED DISEASES | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20230324359-A1 | THERAPEUTIC DRUG FOR LIPID-PEROXIDATION-INDUCED DISEASES AND SCREENING METHOD FOR THERAPEUTIC DRUGS FOR LIPID-PEROXIDATION-INDUCED DISEASES | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20230324358-A1 | THERAPEUTIC DRUG FOR LIPID-PEROXIDATION-INDUCED DISEASES AND SCREENING METHOD FOR THERAPEUTIC DRUGS FOR LIPID-PEROXIDATION-INDUCED DISEASES | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20220023283-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DEMENTIA AND CEREBROVASCULAR DISORDERS | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
| EP-3919052-A1 | PHARMACEUTICAL COMPOSITION FOR INTRAOCULAR OR ORAL ADMINISTRATION FOR TREATMENT OF RETINAL DISEASES | Fuso Pharmaceutical Industries, Ltd. (JP) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020145359-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DEMENTIA AND CEREBROVASCULAR DISORDERS | 山田 健一 | 2020-07-16 | — | — | WO | disclosed |
| WO-2020145364-A1 | PHARMACEUTICAL COMPOSITION FOR INTRAOCULAR OR ORAL ADMINISTRATION FOR TREATMENT OF RETINAL DISEASES | 山田 健一 | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023283-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DEMENTIA AND CEREBROVASCULAR DISORDERS | HTR3B, HTR3A, HTR2A | KDM4E 1814/4885MEN1 1862/4885KMT2A 2764/4885 |
| US-20230324358-A1 | THERAPEUTIC DRUG FOR LIPID-PEROXIDATION-INDUCED DISEASES AND SCREENING METHOD FOR THERAPEUTIC DRUGS FOR LIPID-PEROXIDATION-INDUCED DISEASES | GPX4, GPX1, ALOX15 | KDM4E 4267/4885MEN1 4562/4885KMT2A 4337/4885 |
| US-20230324359-A1 | THERAPEUTIC DRUG FOR LIPID-PEROXIDATION-INDUCED DISEASES AND SCREENING METHOD FOR THERAPEUTIC DRUGS FOR LIPID-PEROXIDATION-INDUCED DISEASES | GPX4, GPX1, ALOX15 | KDM4E 4267/4885MEN1 4562/4885KMT2A 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.